scholarly journals A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain

2015 ◽  
Vol 11 (1) ◽  
Author(s):  
B Duncan X Lascelles ◽  
David Knazovicky ◽  
Beth Case ◽  
Mila Freire ◽  
John F Innes ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Degenerative Joint Disease ◽  
Joint Disease ◽  
Nerve Growth ◽  
And Function

scholarly journals Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Margaret E. Gruen ◽  
Jamie A. E. Myers ◽  
B. Duncan X. Lascelles
Keyword(s):  
Chronic Pain ◽  
Nerve Growth Factor ◽  
Pain Management ◽  
Growth Factor ◽  
Unmet Need ◽  
Degenerative Joint Disease ◽  
Joint Disease ◽  
Efficacy And Safety ◽  
Nerve Growth ◽  
Objectively Measured

Background: Pain management for cats with degenerative joint disease (DJD) remains a critical unmet need. Recent work has shown promise for a feline-specific anti-nerve growth factor monoclonal antibody (frunevetmab) to deliver safe and effective pain management. Our objectives were to evaluate the efficacy and safety of frunevetmab administered twice using two administration routes (subcutaneous and intravenous) compared to placebo.Methods: This was a randomized placebo-controlled, double-masked study. After a week-long pain and activity baseline, 126 cats were randomized to receive injections of frunevetmab (IV then SC; n = 42 or SC then SC; n = 43) or placebo (IV then SC; n = 41) on Days 0 and 28. Owners completed questionnaires on Days 14, 28, 42, and 56. Accelerometry data were collected continuously throughout.Results: Owner questionnaire results showed significant improvement in frunevetmab-treated cats [compared to placebo; (p < 0.05)] at Days 42 and 56; no difference was found between routes of administration for frunevetmab. All groups had decreased objectively measured weekly activity from baseline; frunevetmab-treated cats had a mean decrease of 0.9%, while placebo-treated cats had a mean decrease of 9.3%. Treatments were generally well-tolerated. The majority of adverse events included dermatitis/alopecia related to activity-monitor collars; these occurred in a higher percentage of frunevetmab, compared to placebo, treated cats.Conclusions and Clinical Relevance: Treatment with frunevetmab provided improvements in owner ratings of mobility over treatment with placebo; these results were supported by objectively measured accelerometry. Frunevetmab has the potential to address a critical gap in the treatment of chronic pain in cats.

Administration of nerve growth factor-β to heifers with a pre-ovulatory follicle enhanced luteal formation and function and promoted LH release

2020 ◽  
Vol 148 ◽  
pp. 37-47 ◽  
Author(s):  
Jamie L. Stewart ◽  
Stephanie Stella ◽  
Laís L. Cunha ◽  
Nicholas W. Dias ◽  
Igor F. Canisso ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Nerve Growth ◽  
Ovulatory Follicle ◽  
Lh Release ◽  
And Function

Expression and function of nerve growth factor and nerve growth factor receptors on cultured normal human keratinocytes

1993 ◽  
Vol 6 (1) ◽  
pp. 14
Author(s):  
Carlo Pincelli ◽  
Rossella Manfredini ◽  
Cinzia Sevignani ◽  
Luisa Benassi ◽  
Fabrizio Fantini ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptors ◽  
Human Keratinocytes ◽  
Nerve Growth ◽  
Normal Human Keratinocytes ◽  
Nerve Growth Factor Receptors ◽  
Normal Human ◽  
And Function

Nerve Growth Factor Improves Survival and Function of Transplanted Islets Via TrkA-mediated β Cell Proliferation and Revascularization

2015 ◽  
Vol 99 (6) ◽  
pp. 1132-1143 ◽  
Author(s):  
Tatsuo Hata ◽  
Naoaki Sakata ◽  
Gumpei Yoshimatsu ◽  
Haruyuki Tsuchiya ◽  
Masahiko Fukase ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Β Cell ◽  
Nerve Growth ◽  
And Function

scholarly journals Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function.

1991 ◽  
Vol 88 (5) ◽  
pp. 1709-1715 ◽  
Author(s):  
W D Steers ◽  
S Kolbeck ◽  
D Creedon ◽  
J B Tuttle
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Urinary Bladder ◽  
Nerve Growth ◽  
Form And Function ◽  
And Function

scholarly journals Effect of nerve growth factor on the proliferation in newborn bovine testicular Sertoli cells

Reproduction ◽  
2020 ◽  
Vol 160 (3) ◽  
pp. 405-415
Author(s):  
Qiaoge Niu ◽  
Maosheng Cao ◽  
Chenfeng Yuan ◽  
Yuwen Huang ◽  
Zijiao Zhao ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Signaling Pathways ◽  
Molecular Mechanisms ◽  
Male Reproduction ◽  
Nerve Growth ◽  
And Function

Nerve growth factor (NGF) has been proved to play important roles in male reproductive physiology, but the molecular mechanisms of NGF action remain unclear. In this study, the effects of NGF on the growth of newborn bovine testicular Sertoli (NBS) cells and the related signaling pathways were investigated. The NBS cells were treated in vitro with NGF (100 ng/mL) for 18 h. The expression levels of cell proliferation related genes, INHBB, and cytoplasmic specialization related gene were determined using real-time PCR and Western blot. The roles of PI3K/AKT and MAPK/ERK pathways in NGF-induced cell proliferation were investigated. It was found that NGF regulates proliferation and function of NBS cells via its receptor NTRK1 by activating the PI3K/ATK and MAPK/ERK signaling pathways. The study will help to further understand the role of NGF in male reproduction and provide new therapeutic targets for reproductive dysfunctions in male animals.

Sign in / Sign up

Export Citation Format

Share Document